TARA
Protara Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.33 EPS
Last earnings +1.0% on 2026-05-13
$4.12
▲ +3.00%$4.12▲ +43.06%
over 1Y
L $2.78EODHDH $7.56
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W+0.2%
1M-13.4%
3M-16.6%
YTD-23.4%
1Y+43.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity 0.07x); but unprofitable (net margin -1948.4%).
Revenue (FY2014) $2.95M · FY2014
Protara Therapeutics, Inc. shows $2.95M in FY2014 revenue, a -1948.4% net margin, and -29.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$47.5M | -$67.1M | -$43.6M | -$49.2M | -$64.5M |
| Net income | -$47.3M | -$66.0M | -$40.4M | -$44.6M | -$57.4M |
| Diluted EPS | -$4.21 | -$5.86 | -$3.57 | -$2.17 | -$1.34 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$173M
EV / EBITDA—
EV / Sales58.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-25.8%
FCF yield-25.3%
Quality & risk
ROIC (est.)-26.0%
Free cash flow-$56.5M
Total debt$0.00
Net cash$49.7M
Altman Z-Score8.07 safe
Piotroski F-Score1/6
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+47.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗4Period ending 2026-06-152026-06-16open ↗8-KPeriod ending 2026-06-122026-06-15open ↗4Period ending 2026-06-022026-06-03open ↗424B5Filing2026-05-28open ↗EFFECTFiling2026-05-22open ↗
Frequently asked
- Is Protara Therapeutics, Inc. (TARA) a buy?
- TARA currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.07x); but unprofitable (net margin -1948.4%).
- What is Protara Therapeutics, Inc.'s quality score?
- TARA scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001359931, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 6:58:58 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.